{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT02899091",
      "OrgStudyIdInfo": {
        "OrgStudyId": "CHA-PAD-101"
      },
      "Organization": {
        "OrgFullName": "CHABiotech CO., Ltd",
        "OrgClass": "INDUSTRY"
      },
      "BriefTitle": "Evaluation of the Safety and Potential Therapeutic Effects After Intravenous Transplantation of CB-AC-02 in Patients With Alzheimer's Disease",
      "OfficialTitle": "A Randomized, Double-blind, Placebo-controlled, Phase I / IIa Clinical Trial for Evaluation of Safety and Potential Therapeutic Effect After Transplantation of CB-AC-02 in Patients With Alzheimer's Disease"
    },
    "StatusModule": {
      "StatusVerifiedDate": "September 2019",
      "OverallStatus": "Unknown status",
      "LastKnownStatus": "Recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "September 2016",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "December 2021",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "December 2021",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "September 2, 2016",
      "StudyFirstSubmitQCDate": "September 12, 2016",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "September 14, 2016",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "September 5, 2019",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "September 6, 2019",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "CHABiotech CO., Ltd",
        "LeadSponsorClass": "INDUSTRY"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "The objective of the study is to evaluate the safety and the potential therapeutic effects of CB-AC-02 Intravenous Transplantation in patients with Alzheimer' disease comprised of 2 treatment cohorts:"
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Alzheimer's Disease"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Alzheimer's disease",
          "Mesenchymal Stem cells"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "Triple",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Participant",
              "Care Provider",
              "Investigator"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "24",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "CB-AC-02",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Subjects with Alzheimer's disease Intervention: CB-AC-02",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: CB-AC-02"
              ]
            }
          },
          {
            "ArmGroupLabel": "Placebo",
            "ArmGroupType": "Placebo Comparator",
            "ArmGroupDescription": "Subjects with Alzheimer's disease Intervention: Placebo",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Placebo"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "CB-AC-02",
            "InterventionDescription": "Stage1:\n\n① Group1: CB-AC-02, 2.0 x 10^8 cells on day 0\n\n② Group2: CB-AC-02, 2.0 x 10^8 cells, on day 0 and on week 4 (repeated injection)\n\nStage2\n\n① Arm1: K-MMSE 20~26 CB-AC-02, 2.0 x 10^8 cells on day 0 and on week 4 (repeated injection)\n\n② Arm2: K-MMSE 10~19 CB-AC-02, 2.0 x 10^8 cells on day 0 and on week 4 (repeated injection)",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "CB-AC-02"
              ]
            }
          },
          {
            "InterventionType": "Biological",
            "InterventionName": "Placebo",
            "InterventionDescription": "Stage2:\n\nPlacebo on day 0 and on week 4 (repeated injection)",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Placebo"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Number of Adverse Events",
            "PrimaryOutcomeDescription": "Number of subjects with treatment-related adverse events.\n\nThe safety and tolerability of treatment with CB-AC-02 will be assessed by analysis of adverse events, abnormal findings on physical examinations, standard laboratory tests.",
            "PrimaryOutcomeTimeFrame": "48 weeks"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Changes from the baseline in ADAS-Cog (Azheimer's disease Assessment Scale - Congintive Subscale) Score",
            "SecondaryOutcomeTimeFrame": "48 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Changes from the baseline in K-MMSE (Korean-Mini Mental Status Examination) Score",
            "SecondaryOutcomeTimeFrame": "48 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Changes from the baseline in GDS (Global Deterioration Scale)",
            "SecondaryOutcomeTimeFrame": "48 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Changes from the baseline in CDR (Clinical Dementia Rating) Score",
            "SecondaryOutcomeTimeFrame": "48 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Changes from the baseline in K-IADL (Korean Instrumental Activities of Daily Living) Score",
            "SecondaryOutcomeTimeFrame": "48 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Changes from the baseline in CGA-NPI (Caregiver Administered-Neuropsychiatric Inventory) Score",
            "SecondaryOutcomeTimeFrame": "48 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Change in CIBIC (Clinician Interview Based Impression of Change)-plus",
            "SecondaryOutcomeTimeFrame": "48 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Changes from the baseline in SF-36",
            "SecondaryOutcomeTimeFrame": "48 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Changes in Amyloid Beta and Tau amount (pg/mL) in CSF (Cerebrospinal fluid)",
            "SecondaryOutcomeTimeFrame": "48 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Change in Brain MRI (Magnetic Responance imaging)",
            "SecondaryOutcomeTimeFrame": "48 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Change from the baseline of CMRglc (cerebral metabolic rate for glucose ) analyzed with SPM (statistical parametric mapping) with Brain FDG PET imaging",
            "SecondaryOutcomeTimeFrame": "48 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Changes from the baseline of Amyloid amount analyzed with SPM (statistical parametric mapping) with amyloid PET imaging",
            "SecondaryOutcomeTimeFrame": "48 weeks"
          },
          {
            "SecondaryOutcomeMeasure": "Changes of band power in qEEG (Quantitative electroencephalography)",
            "SecondaryOutcomeTimeFrame": "48 weeks"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nKorean male or female at 50+ years of age at the time of screening visit\nDiagnosis of Probable Alzheimer disease (probable AD) according to NINCDS-ADRDA criteria at Screening visit\nPositive for Amyloid on amyloid-ligand PET\n\nA subject with the imaging findings of Alzheimer's disease as confirmed by MRI or PET\n\nPresence of brain atrophy on brain MRI by visual assessment\nPresence of reduced brain glucose metabolism in bilateral temporal-parietal lobe on FDG-PET\nKorea Mini-Mental State Examination (KMMSE) score of 10-26 at time of screening visit\nPresence of caregiver who can provide information on the subject's condition\nSubject who has been taking stable dose of Alzheimer medication for last 2 months or more\nSubject who is informed of the clinical trial and signs a consent form (if unable to sign, a consent from a legally acceptable representative is required)\n\nExclusion Criteria:\n\nConcurrent Dementia as a result of other disorders [i.e. infectious disease of the central nervous system such as HIV, syphilis, head injury, Creutzfeld-Jacob disease, Picks disease, Huntington's disease, Parkinson's disease, other subdural hematoma, hydrocephalus and structural brain lesions, drug addiction, alcoholism, substance abuse, thyroid disease, parathyroid disease, vitamins and other nutritional deficiencies and vascular etc.]\nSubject with vascular dementia as determined by the clinical criteria of DSM-IV and the imaging criteria of Erkinkuntii\nSubject with severe white matter hyperintensities (i.e. ≥ 25mm of the deep white matter and ≥ 10mm of the periventricular capping/banding in lengths)\n\nAbnormal laboratory findings at screening visit:\n\nA. ALT or AST ≥ 2.5 times the upper limit of normal value\n\nB. Serum creatinine ≥ 1.5 times the upper limit of normal value\n\nC. Total bilirubin ≥ 2 times the upper limit of normal value\n\nD. Total WBC counts < 3,000/㎣\n\nE. Hemoglobin <9.5g/dL in men or <9.0g/dL in women\n\nF. Platelet count < 150,000/㎣ at screening visit\n\nG. PT (INR) ≥ 1.5 or aPTT ≥ 1.5 times the upper limit of normal value\n\nSubjects who are positive for HIV, syphilis or active HBV, HCV infection\nSubjects in poor medical condition or subjects with severe cardiovascular, gastrointestinal, pulmonary or endocrinologic disease A. Suspected active active lung disease on chest X-ray at screening visit B. Diagnosis of cancer (except for the subjects who remains in complete remission for 5 years or more )\nSubject with concurrent unstable psychiatric disorder (i.e. severe depression, or schizophrenia, or bipolar disorder, etc)\nPregnant or lactating women\n\nWomen of childbearing age who reject to practice contraception with one of the following methods\n\nUse a condom\nUse of contraceptive (oral, dermal, or injectable)\nUse an intra-uterine contraceptive device\nSubjects with a history of alcohol abuse (>30g/day) or drug abuse\nSubjects who cannot undergo any of the tests performed in this clinical trial (for example, MRI, CT, PET, CSF study)\nSubjects with known allergies to protein products (Bovine serum), antibiotics (gentamycin) or DMSO\nSubjects whom the principal investigator considers inappropriate for participation in theis study",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "50 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Hye Sun Kim",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "+82-31-881-7431",
            "CentralContactEMail": "goldfish79@chamc.co.kr"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Bundang Medical Center",
            "LocationStatus": "Recruiting",
            "LocationCity": "Seongnam-si",
            "LocationState": "Gyeonggi-do",
            "LocationCountry": "Korea, Republic of",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "HyunSook Kim, MD, PhD",
                  "LocationContactRole": "Contact"
                }
              ]
            }
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000000544",
            "ConditionMeshTerm": "Alzheimer Disease"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000003704",
            "ConditionAncestorTerm": "Dementia"
          },
          {
            "ConditionAncestorId": "D000001927",
            "ConditionAncestorTerm": "Brain Diseases"
          },
          {
            "ConditionAncestorId": "D000002493",
            "ConditionAncestorTerm": "Central Nervous System Diseases"
          },
          {
            "ConditionAncestorId": "D000009422",
            "ConditionAncestorTerm": "Nervous System Diseases"
          },
          {
            "ConditionAncestorId": "D000024801",
            "ConditionAncestorTerm": "Tauopathies"
          },
          {
            "ConditionAncestorId": "D000019636",
            "ConditionAncestorTerm": "Neurodegenerative Diseases"
          },
          {
            "ConditionAncestorId": "D000019965",
            "ConditionAncestorTerm": "Neurocognitive Disorders"
          },
          {
            "ConditionAncestorId": "D000001523",
            "ConditionAncestorTerm": "Mental Disorders"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M3037",
            "ConditionBrowseLeafName": "Alzheimer Disease",
            "ConditionBrowseLeafAsFound": "Alzheimer's Disease",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M6056",
            "ConditionBrowseLeafName": "Dementia",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4356",
            "ConditionBrowseLeafName": "Brain Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4894",
            "ConditionBrowseLeafName": "Central Nervous System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M22155",
            "ConditionBrowseLeafName": "Tauopathies",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M20711",
            "ConditionBrowseLeafName": "Neurodegenerative Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M20989",
            "ConditionBrowseLeafName": "Neurocognitive Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M3967",
            "ConditionBrowseLeafName": "Mental Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M13625",
            "ConditionBrowseLeafName": "Psychotic Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "T2192",
            "ConditionBrowseLeafName": "Familial Alzheimer Disease",
            "ConditionBrowseLeafAsFound": "Alzheimer's Disease",
            "ConditionBrowseLeafRelevance": "high"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC10",
            "ConditionBrowseBranchName": "Nervous System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BXM",
            "ConditionBrowseBranchName": "Behaviors and Mental Disorders"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "Rare",
            "ConditionBrowseBranchName": "Rare Diseases"
          }
        ]
      }
    }
  }
}